Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 1/2019

01-01-2019 | Original Research

Circulating Levels of Inflammation and the Effect on Exercise-Related Changes in Bone Mass, Structure and Strength in Middle-Aged and Older Men

Authors: Jack Dalla Via, Rachel L. Duckham, Jonathan M. Peake, Sonja Kukuljan, Caryl A. Nowson, Robin M. Daly

Published in: Calcified Tissue International | Issue 1/2019

Login to get access

Abstract

Chronic, low-grade systematic inflammation has been associated with bone loss and increased fracture risk. We previously reported that exercise improved femoral neck bone mineral density (BMD), geometry and strength and lumbar spine trabecular BMD in middle-aged and older men, but had no effect on markers of inflammation. The aim of this study was to examine the association between basal inflammatory status and the adaptive skeletal responses to exercise. Secondary analysis was completed on 91 men aged 50–79 years who participated in an 18-month program of progressive resistance training plus weight-bearing impact exercise (3 day/week) with and without additional calcium–vitamin D3. Markers of inflammation (serum hs-CRP, TNF-α and IL-6) and DXA and QCT-derived BMD, bone structure and strength at the lumbar spine and proximal femur were measured at baseline and 18 months. Multiple regression was used to assess associations between skeletal changes and both baseline levels of individual inflammatory markers and a composite inflammatory index derived from the number of markers categorized into the highest tertile. Baseline serum hs-CRP, TNFα and IL-6 and the composite inflammatory index score were not associated with skeletal changes at any site after adjusting for age, change in lean mass, disease(s)/medication use and adherence to the exercise intervention. In conclusion, this study indicates that basal inflammatory status does not influence the osteogenic response to exercise training in healthy middle-aged and older men.
Literature
1.
Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB (2007) Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 22(7):1088–1095CrossRefPubMed
2.
Ding C, Parameswaran V, Udayan R, Burgess J, Jones G (2008) Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 93(5):1952–1958CrossRefPubMed
3.
Koh J-M, Khang Y-H, Jung C-H, Bae S, Kim DJ, Chung Y-E, Kim GS (2005) Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre-and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 16(10):1263–1271CrossRefPubMed
4.
Nakamura K, Saito T, Kobayashi R, Oshiki R, Oyama M, Nishiwaki T, Nashimoto M, Tsuchiya Y (2011) C-reactive protein predicts incident fracture in community-dwelling elderly Japanese women: the Muramatsu study. Osteoporos Int 22(7):2145–2150CrossRefPubMed
5.
Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J (2001) Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 86(5):2032–2042PubMed
6.
Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166(22):2495–2501CrossRefPubMed
7.
Ishii S, Cauley JA, Greendale GA, Crandall CJ, Danielson ME, Ouchi Y, Karlamangla AS (2013) C-reactive protein, bone strength, and nine-year fracture risk: data from the study of women’s health across the nation (SWAN). J Bone Miner Res 28(7):1688–1698CrossRefPubMed
8.
Abbas S, Clohisy J, Abu-Amer Y (2003) Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21(6):1041–1048CrossRefPubMed
9.
Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL (2000) Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275(35):27307–27310PubMed
10.
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319(6053):516–518CrossRef
11.
Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RGG (1983) An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306(5941):378–380CrossRefPubMed
12.
Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T (1990) IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145(10):3297–3303PubMed
13.
Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC (1992) Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 275:88–91CrossRef
14.
Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R (1995) Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136(7):3054–3061CrossRefPubMed
15.
Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, Gronowicz G, Kalinowski J, Pilbeam CC (1998) Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139(6):3022–3025CrossRefPubMed
16.
Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13(5):1189CrossRefPubMedPubMedCentral
17.
Clowes JA, Riggs BL, Khosla S (2005) The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 208(1):207–227CrossRefPubMed
18.
Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311CrossRefPubMed
19.
Troen BR (2003) Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38(6):605–614CrossRefPubMed
20.
Shea MK, Dallal GE, Dawson-Hughes B, Ordovas JM, O’donnell CJ, Gundberg CM, Peterson JW, Booth SL (2008) Vitamin K, circulating cytokines, and bone mineral density in older men and women. Am J Clin Nutr 88(2):356–363CrossRefPubMedPubMedCentral
21.
Sponholtz TR, Zhang X, Fontes JD, Meigs JB, Cupples LA, Kiel DP, Hannan MT, McLean RR (2014) Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women. Arthritis Care Res (Hoboken) 66(8):1233–1240CrossRef
22.
Berglundh S, Malmgren L, Luthman H, McGuigan F, Åkesson K (2015) C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int 26(2):727–735CrossRefPubMed
23.
24.
Kohut M, McCann D, Russell D, Konopka D, Cunnick J, Franke W, Castillo M, Reighard A, Vanderah E (2006) Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of β-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun 20(3):201–209CrossRefPubMed
25.
Nicklas BJ, Hsu FC, Brinkley TJ, Church T, Goodpaster BH, Kritchevsky SB, Pahor M (2008) Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc 56(11):2045–2052CrossRefPubMedPubMedCentral
26.
Phillips MD, Mitchell JB, Currie-Elolf LM, Yellott RC, Hubing KA (2010) Influence of commonly employed resistance exercise protocols on circulating IL-6 and indices of insulin sensitivity. J Strength Cond Res 24(4):1091–1101CrossRefPubMed
27.
Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E (2005) Influence of exercise training and age on CD14 + cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun 19(5):389–397CrossRefPubMed
28.
Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, Timmerman KL, McFarlin BK, Coen PM, Talbert E (2007) The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 39(10):1714–1719CrossRefPubMed
29.
Thompson D, Markovitch D, Betts JA, Mazzatti D, Turner J, Tyrrell RM (2010) Time course of changes in inflammatory markers during a 6-mo exercise intervention in sedentary middle-aged men: a randomized-controlled trial. J Appl Physiol (1985) 108(4):769–779CrossRefPubMed
30.
Ploeger HE, Takken T, De Greef M, Timmons BW (2009) The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc Immunol Rev 15(1):6–41PubMed
31.
Silverman NE, Nicklas BJ, Ryan AS (2009) Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal women. Calcif Tissue Int 84(4):257–265CrossRefPubMedPubMedCentral
32.
33.
Kukuljan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, Daly RM (2011) Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. J Clin Endocrinol Metab 96(4):955–963CrossRefPubMed
34.
Kukuljan S, Nowson C, Bass S, Sanders K, Nicholson G, Seibel M, Salmon J, Daly R (2009) Effects of a multi-component exercise program and calcium–vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial. Osteoporos Int 20(7):1241–1251CrossRefPubMed
35.
Peake JM, Kukuljan S, Nowson CA, Sanders K, Daly RM (2011) Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50 + years: an 18-month randomized controlled trial. Eur J Appl Physiol 111(12):3079–3088CrossRefPubMed
36.
American College of Sports Medicine (2000) ACSM’s guidelines for exercise testing and prescription, 6th edn. Lippincott Williams & Wilkins, Philadelphia
37.
Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL (2001) CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc 33(7):1126–1141CrossRefPubMed
38.
Crabtree N, Lunt M, Holt G, Kroger H, Burger H, Grazio S, Khaw K-T, Lorenc R, Nijs J, Stepan J (2000) Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. Bone 27(1):151–159CrossRefPubMed
39.
Daly RM, Bass S, Nowson C (2006) Long-term effects of calcium–vitamin-D 3-fortified milk on bone geometry and strength in older men. Bone 39(4):946–953CrossRefPubMed
40.
Sievänen H (2000) A physical model for dual-energy X-ray absorptiometry–derived bone mineral density. Invest Radiol 35(5):325–330CrossRefPubMed
41.
Lee Y, Kim M, Choi K, Kim J, Bae W, Kim S, Sohn C (2011) Relationship between inflammation biomarkers, antioxidant vitamins, and bone mineral density in patients with metabolic syndrome. Nutr Res Pract 5(2):150–156CrossRefPubMedPubMedCentral
42.
Pasco JA, Kotowicz MA, Henry MJ, Nicholson GC, Spilsbury HJ, Box JD, Schneider HG (2006) High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 296(11):1349–1355CrossRef
Metadata
Title
Circulating Levels of Inflammation and the Effect on Exercise-Related Changes in Bone Mass, Structure and Strength in Middle-Aged and Older Men
Authors
Jack Dalla Via
Rachel L. Duckham
Jonathan M. Peake
Sonja Kukuljan
Caryl A. Nowson
Robin M. Daly
Publication date
01-01-2019
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2019
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-018-0475-4

Other articles of this Issue 1/2019

Calcified Tissue International 1/2019 Go to the issue

Original Research

Vitamin D and Bone Mineral Density in HIV Newly Diagnosed Therapy-Naive Patients Without Any Secondary Causes of Osteoporosis

Original Research

Metformin Alleviates the Bone Loss Induced by Ketogenic Diet: An In Vivo Study in Mice

Original Research

Atrophic Gastritis as a Risk Factor for Bone Loss in Premenopausal Women in Their 40s: A Retrospective Cohort Study

Original Research

Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling

Original Research

Bone Mass Development in Childhood and Its Association with Physical Activity and Vitamin D Levels. The CHAMPS-Study DK

Original Research

OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits